Literature DB >> 19409384

PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.

Christine Flaiz1, Jonathan Chernoff, Sylwia Ammoun, Jeffrey R Peterson, Clemens O Hanemann.   

Abstract

Merlin loss causes benign tumours of the nervous system, mainly schwannomas and meningiomas. Schwannomas show enhanced Rac1 and Cdc42 activity, the p21-activated kinase 2 (PAK2) activation and increased ruffling and cell adhesion. PAK regulates activation of merlin. PAK has been proposed as a potential therapeutic target in schwannomas. However where PAK stands in the Rac pathway is insufficiently characterised. We used a novel small-molecule PAK inhibitor, IPA-3, to investigate the role of PAK activation on Rac1/Cdc42 activity, cell spreading and adhesion in human primary schwannoma and Schwann cells. We show that IPA-3 blocks activation of PAK2 at Ser192/197 that antagonises PAK's interaction with Pix. Accordingly, Pix-mediated Rac1 activation is decreased in IPA-3 treated schwannoma cells, indicating that PAK acts upstream of Rac. We show that this Rac activation at the level of focal adhesions in schwannoma cells is essential for cell spreading and adhesion in Schwann and schwannoma cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19409384      PMCID: PMC2760977          DOI: 10.1016/j.expneurol.2009.04.019

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  33 in total

Review 1.  The lamellipodium: where motility begins.

Authors:  J Victor Small; Theresia Stradal; Emmanuel Vignal; Klemens Rottner
Journal:  Trends Cell Biol       Date:  2002-03       Impact factor: 20.808

Review 2.  Biology of the p21-activated kinases.

Authors:  Gary M Bokoch
Journal:  Annu Rev Biochem       Date:  2003-03-27       Impact factor: 23.643

3.  The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors.

Authors:  A J Ridley; A Hall
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

4.  An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.

Authors:  Sean W Deacon; Alexander Beeser; Jami A Fukui; Ulrike E E Rennefahrt; Cynthia Myers; Jonathan Chernoff; Jeffrey R Peterson
Journal:  Chem Biol       Date:  2008-04

5.  The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling.

Authors:  R J Shaw; J G Paez; M Curto; A Yaktine; W M Pruitt; I Saotome; J P O'Bryan; V Gupta; N Ratner; C J Der; T Jacks; A I McClatchey
Journal:  Dev Cell       Date:  2001-07       Impact factor: 12.270

6.  A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.

Authors:  Yumiko Hirokawa; Anjali Tikoo; John Huynh; Tamara Utermark; C Oliver Hanemann; Marco Giovannini; Guang-Hui Xiao; Joseph R Testa; John Wood; Hiroshi Maruta
Journal:  Cancer J       Date:  2004 Jan-Feb       Impact factor: 3.360

7.  Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins.

Authors:  Tamara Utermark; Katherine Kaempchen; C Oliver Hanemann
Journal:  Brain Pathol       Date:  2003-07       Impact factor: 6.508

8.  NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions.

Authors:  Dominique Lallemand; Marcello Curto; Ichiko Saotome; Marco Giovannini; Andrea I McClatchey
Journal:  Genes Dev       Date:  2003-04-14       Impact factor: 11.361

9.  Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells.

Authors:  Katherine Kaempchen; Kirsten Mielke; Tamara Utermark; Sonja Langmesser; C Oliver Hanemann
Journal:  Hum Mol Genet       Date:  2003-06-01       Impact factor: 6.150

10.  Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1.

Authors:  Joseph L Kissil; Erik W Wilker; Kristen C Johnson; Matthew S Eckman; Michael B Yaffe; Tyler Jacks
Journal:  Mol Cell       Date:  2003-10       Impact factor: 17.970

View more
  20 in total

Review 1.  RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.

Authors:  Hemant K Bid; Ryan D Roberts; Parmeet K Manchanda; Peter J Houghton
Journal:  Mol Cancer Ther       Date:  2013-09-26       Impact factor: 6.261

2.  Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides.

Authors:  Wei Ying Yue; J Jason Clark; Augusta Fernando; Frederick Domann; Marlan R Hansen
Journal:  Neuro Oncol       Date:  2011-06-22       Impact factor: 12.300

Review 3.  Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer.

Authors:  Chunling Yi; Jasna Maksimoska; Ronen Marmorstein; Joseph L Kissil
Journal:  Biochem Pharmacol       Date:  2010-03-17       Impact factor: 5.858

Review 4.  Approaches of targeting Rho GTPases in cancer drug discovery.

Authors:  Yuan Lin; Yi Zheng
Journal:  Expert Opin Drug Discov       Date:  2015-06-18       Impact factor: 6.098

5.  What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.

Authors:  Joseph L Kissil; Jaishri O Blakeley; Rosalie E Ferner; Susan M Huson; Michel Kalamarides; Victor-Felix Mautner; Frank McCormick; Helen Morrison; Roger Packer; Vijaya Ramesh; Nancy Ratner; Katherine A Rauen; David A Stevenson; Kim Hunter-Schaedle; Kathryn North
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

6.  p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.

Authors:  Hoi Yee Chow; Dina Stepanova; Jennifer Koch; Jonathan Chernoff
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

7.  Do PAKs make good drug targets?

Authors:  Zhuo-Shen Zhao; Ed Manser
Journal:  F1000 Biol Rep       Date:  2010-09-23

8.  FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.

Authors:  Silvia Licciulli; Jasna Maksimoska; Chun Zhou; Scott Troutman; Smitha Kota; Qin Liu; Sergio Duron; David Campbell; Jonathan Chernoff; Jeffrey Field; Ronen Marmorstein; Joseph L Kissil
Journal:  J Biol Chem       Date:  2013-08-19       Impact factor: 5.157

9.  p21-activated kinase 2 regulates HSPC cytoskeleton, migration, and homing via CDC42 activation and interaction with β-Pix.

Authors:  Pavankumar N G Reddy; Maria Radu; Ke Xu; Jenna Wood; Chad E Harris; Jonathan Chernoff; David A Williams
Journal:  Blood       Date:  2016-03-01       Impact factor: 22.113

10.  p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.

Authors:  Iram Ahmad; Wei Ying Yue; Augusta Fernando; J Jason Clark; Erika A Woodson; Marlan R Hansen
Journal:  Glia       Date:  2014-06-26       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.